drugset / Trial / NCT01779271

Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection

NCT01779271

Phase 3 Completed 183 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

Multi-center, Randomized, Double blind, Controlled Parallel-group Comparative Phase 3 Clinical trial to assess the efficacy and safety of Pelubiprofen Compared to Loxoprofen in patients with Acute upper respiratory infection.

Timeline

Start
2013-01
Primary completion
2016-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Loxoprofen Small molecule 60 mg
Subject Pelubiprofen Small molecule 30 mg